Automated CT Measurement of Total Kidney Volume for Predicting Renal Function Decline after 177Lu Prostate-specific Membrane Antigen–I&T Radioligand Therapy
A decrease in total kidney volume after lutetium 177 prostate-specific membrane antigen radioligand therapy predicted renal function decline at 12 months in patients with metastatic castration-resistant prostate cancer.